Latest news with #RothCapitalPartners
Business Insider
an hour ago
- Business
- Business Insider
Moleculin Biotech files to sell 10.99M shares of common stock, warrants
Roth Capital Partners is acting as manager. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
3 days ago
- Business
- Yahoo
Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering
Revelation Biosciences, Inc. (NASDAQ:REVB), a clinical-stage life sciences company dedicated to rebalancing inflammation for improved health outcomes, has successfully closed a public offering, raising approximately $4 million in gross proceeds. The offering included 3,640,000 shares of common stock (or equivalents) and warrants to purchase up to 14,560,000 shares, all priced at $1.10 per share and warrant. The warrants, exercisable upon shareholder approval, will remain valid for five years from their initial exercise date. Roth Capital Partners served as the sole placement agent for the transaction. A female doctor using the latest healthcare IT technology in her medical practice. Revelation Biosciences, Inc. (NASDAQ:REVB) plans to use the net proceeds to advance its clinical and preclinical programs. Key initiatives include completing its ongoing Phase 1b clinical trial, manufacturing clinical drug supplies, conducting additional preclinical studies for multiple indications, developing new products and therapies, and supporting general corporate operations. While we acknowledge the potential of REVB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMZN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
4 days ago
- Business
- Yahoo
Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering
Revelation Biosciences, Inc. (NASDAQ:REVB), a clinical-stage life sciences company dedicated to rebalancing inflammation for improved health outcomes, has successfully closed a public offering, raising approximately $4 million in gross proceeds. The offering included 3,640,000 shares of common stock (or equivalents) and warrants to purchase up to 14,560,000 shares, all priced at $1.10 per share and warrant. The warrants, exercisable upon shareholder approval, will remain valid for five years from their initial exercise date. Roth Capital Partners served as the sole placement agent for the transaction. A female doctor using the latest healthcare IT technology in her medical practice. Revelation Biosciences, Inc. (NASDAQ:REVB) plans to use the net proceeds to advance its clinical and preclinical programs. Key initiatives include completing its ongoing Phase 1b clinical trial, manufacturing clinical drug supplies, conducting additional preclinical studies for multiple indications, developing new products and therapies, and supporting general corporate operations. While we acknowledge the potential of REVB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMZN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
6 days ago
- Business
- Associated Press
ROTH Announces the Addition of Kyle Bauser, Ph.D. to its Healthcare Research Team
NEWPORT BEACH, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- via IBN – Roth Capital Partners ('ROTH'), today announced Kyle Bauser, Ph.D., as Managing Director, Senior Research Analyst. Dr. Bauser has joined the firm's healthcare research team, covering the medical technology sector. He has over a decade of MedTech experience across equity research and industry. Dr. Bauser began his career in MedTech equity research over 12 years ago at Piper Sandler. He later worked in marketing and corporate development at Vascular Solutions before returning to research at Dougherty & Co, where he became Managing Director and Co-Head of Equity Capital Markets. His research primarily focuses on small- to mid-cap and underfollowed companies with novel technologies. He studied Mathematical Economics and Pre-Med at Colorado College as an undergraduate and earned a Ph.D. in Economics from the City University of New York Graduate Center. Jeff Martin, CFA, Co-Director of Research & Senior Research Analyst at ROTH, commented, 'I'm pleased to welcome Kyle to our healthcare research team. I am confident his strong research background and understanding of equity markets in MedTech will serve our clients well.' 'We are committed to expanding our research department across industries and market caps', said Sagar Sheth, CEO of ROTH. 'I'm confident that Kyle's expertise will provide valuable insights for our clients and help expand our healthcare practice.' Dr. Bauser noted, 'I am thrilled to be joining the impressive ROTH platform, which has a full suite of offerings dedicated to small-cap growth companies. I look forward to collaborating with the team and utilizing my diverse set of experiences to identify unique MedTech opportunities for our clients.' Since 2010, ROTH has been involved in over 600 transactions for its healthcare clients, with a total transaction value of over $25 Billion. (Source: ROTH 05.21.25) About ROTH: ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, Roth is a privately held, employee-owned organization and maintains offices throughout the U.S. For more information on Roth, please visit Investor Contact ROTH Isabel Mattson-Pain Managing Director, Chief Marketing Officer [email protected] | 949.720.7117 ROTH – Member FINRA/SIPC – Wire Service Contact: IBN Austin, Texas 512.354.7000 Office [email protected]
Bloomberg
24-05-2025
- Business
- Bloomberg
Fate of $20 Billion US Home Solar Market Lies in GOP Senate Hands
The troubled, $20 billion US residential solar market's future rests on whether Senate Republicans will challenge their brethren in the House of Representatives and change provisions of the massive tax and spending bill that executives and analysts alike say would devastate the industry. The bill passed by the House this week would strip away tax credits for companies that lease rooftop solar systems as well as homeowners who buy them outright. The industry is already reeling from tariffs on imported equipment, high interest rates and reduced state incentives in California, the nation's biggest residential solar market. One major rooftop solar company — Sunnova Energy International Inc. — is laying the groundwork for a bankruptcy filing, and analyst Philip Shen at Roth Capital Partners warned the bill as written would effectively shut down the industry, starting next year.
